HCV displays considerable levels of nucleotide and amino acid diversity. Recently, the relevance of natural polymorphisms in worldwide isolates has been addressed in view of future protease inhibitor (PI)-based treatments; genotype- and subtype-specific natural polymorphisms within HCV NS3 protease were identified at amino acid sites associated either with resistance to PIs or with compensatory mutations. Here, we describe a case of chronic infection with HCV of genotype 3 subtype h (HCV-3h), formerly only described from three patients originating from Somalia, and we provide the first NS3 protease sequence for such strains. NS3 protease sequences of HCV-3h recovered in the present study harbour specific amino acid residues not encountered in other reference HCV genotypes and subtypes at nine of the 181 NS3 protease positions; none of these amino acids are known to confer resistance to PIs. Of note, 5’ untranslated region sequence-based genotyping classifies them into genotype 1.
References
1.
SimmondsP., BukhJ., CombetC.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology2005; 42: 962–973.
López-LabradorF.X., MoyaA., Gonzàlez-CandelasF.Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther2008; 13: 481–494.
4.
Peres-da-SilvaA., de AlmeidaA.J., LampeE.Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol2010; 155: 807–811.
5.
AbidK., QuadriR., VeutheyA.L., HadengueA., NegroF.A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3. J Gen Virol2000; 81: 1485–1493.
6.
BernierL., WillemsB., DelageG., MurphyD.G.Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol1996; 34: 2815–2818.
7.
TamaletC., ColsonP., Tissot-DupontH.Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol2003; 71: 391–398.
8.
ColsonP., BroukN., LemboF., CastellaniP., TamaletC., GérolamiR.Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology2008; 47: 766–767.
9.
PawlotskyJ.M.Therapy of hepatitis C: from empiricism to eradication. Hepatology2006; 43Suppl 1: S207–S220.
10.
SarrazinC., ZeuzemS.Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology2010; 138: 447–462.
11.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
12.
ThibeaultD., BousquetC., GingrasR.Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol2004; 78: 7352–7359.
13.
LuL., Pilot-MatiasT.J., StewartK.D.Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother2004; 48: 2260–2266.
14.
BowdenD.S., BerzsenyiM.D.Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol2006; 1: 103–112.
15.
ChevaliezS., Bouvier-AliasM., BrilletR., PawlotskyJ.M.Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE2009; 4: e8209.
16.
EdgarR.C.MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res2004; 32: 1792–1797.